MDS Abstracts

Abstracts from the International Congress of Parkinson’s and Movement Disorders.

MENU 
  • Home
  • Meetings Archive
    • 2024 International Congress
    • 2023 International Congress
    • 2022 International Congress
    • MDS Virtual Congress 2021
    • MDS Virtual Congress 2020
    • 2019 International Congress
    • 2018 International Congress
    • 2017 International Congress
    • 2016 International Congress
  • Keyword Index
  • Resources
  • Advanced Search

Progress of the UK Cholinesterase inhibitor to prevent falls in Parkinson’s disease (CHIEF-PD) trial

A. Bamford, S. Neumann, J. Taylor, G. Young, S. Emmett, W. Hollingworth, A. Whone, D. Steeds, C. Metcalfe, Y. Ben-Shlomo, E. Henderson (Bristol, United Kingdom)

Meeting: 2022 International Congress

Abstract Number: 691

Keywords: Cholinesterase inhibitors, Gait disorders: Treatment, Parkinson’s

Category: Parkinson’s Disease: Clinical Trials

Objective: This abstract provides an overview of the progress of the CHIEF-PD trial.

Background: Falls are a common and debilitating consequence of Parkinson’s disease (PD). Falls are associated with significant morbidity and mortality including soft tissue injuries and fractures, hospital admissions as well as fear of falling. Cholinesterase inhibitors are established for the treatment of PD dementia and phase II trials have established the potential efficacy in fall prevention in PD. Further evidence is required to establish the clinical and cost-effectiveness.

Method: CHolinesterase Inhibitors to prEvent Falls in Parkinson’s Disease (CHIEF-PD) is a National Institute of Health Research funded, phase III, double blind randomised controlled trial of rivastigmine versus placebo for the prevention of falls in idiopathic Parkinson’s disease (PD). The trial will recruit 600 patients with PD across sites in the UK. Participants are eligible if they have iPD, have fallen in the year prior to enrolment, can walk 10m unaided and do not have dementia and are not using ChEis. Participants are enroled for one year and are prescribed transdermal rivastigmine (or matched placebo) 4.6mg for one month, 9.5mg for five months and 13.3mg for six months, as tolerated. The primary outcome is fall rate.

Results: The trial is recruiting across 33 centers in the UK with sites having recruited between 0 and 56 patients. As of 28th February 2022, 229 participants had been enroled. 11 participants have withdrawn due to burden of participation (7), intercurrent health issues (1) death (1) and reasons unknown (2). Of the enroled participants, 31 have discontinued the active / placebo patches largely secondary to already described side effects. 23 Serious Adverse Events have been reported and 4 of these have been possibly, probably or definitely related to the active / placebo patches.

Conclusion: The CHIEF-PD trial continues to recruit participants with iPD who have experienced a fall for randomisation to rivastigmine or matched placebo transdermal patches.  The trial is recruiting well across multiple centres and the retention of participants remains above that predicted. The results of the CHIEF-PD trial will provide definitive evidence as to the clinical and cost-effectiveness for cholinesterase inhibitors for fall prevention in PD.

References: The CHIEF-PD trial continues to recruit participants with iPD who have experienced a fall for randomisation to rivastigmine or matched placebo transdermal patches. The trial is recruiting well across multiple centres and the retention of participants remains above that predicted. The results of the CHIEF-PD trial will provide definitive evidence as to the clinical and cost-effectiveness for cholinesterase inhibitors for fall prevention in PD.

To cite this abstract in AMA style:

A. Bamford, S. Neumann, J. Taylor, G. Young, S. Emmett, W. Hollingworth, A. Whone, D. Steeds, C. Metcalfe, Y. Ben-Shlomo, E. Henderson. Progress of the UK Cholinesterase inhibitor to prevent falls in Parkinson’s disease (CHIEF-PD) trial [abstract]. Mov Disord. 2022; 37 (suppl 2). https://www.mdsabstracts.org/abstract/progress-of-the-uk-cholinesterase-inhibitor-to-prevent-falls-in-parkinsons-disease-chief-pd-trial/. Accessed July 11, 2025.
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to 2022 International Congress

MDS Abstracts - https://www.mdsabstracts.org/abstract/progress-of-the-uk-cholinesterase-inhibitor-to-prevent-falls-in-parkinsons-disease-chief-pd-trial/

Most Viewed Abstracts

  • This Week
  • This Month
  • All Time
  • What is the appropriate sleep position for Parkinson's disease patients with orthostatic hypotension in the morning?
  • Covid vaccine induced parkinsonism and cognitive dysfunction
  • Life expectancy with and without Parkinson’s disease in the general population
  • Estimation of the 2020 Global Population of Parkinson’s Disease (PD)
  • To be or not to bupropion: a drug-induced parkinsonism?
  • Covid vaccine induced parkinsonism and cognitive dysfunction
  • What is the appropriate sleep position for Parkinson's disease patients with orthostatic hypotension in the morning?
  • Life expectancy with and without Parkinson’s disease in the general population
  • An atypical and interesting feature of Parkinson´s disease
  • Estimation of the 2020 Global Population of Parkinson’s Disease (PD)
  • Effect of marijuana on Essential Tremor: A case report
  • Increased Risks of Botulinum Toxin Injection in Patients with Hypermobility Ehlers Danlos Syndrome: A Case Series
  • Covid vaccine induced parkinsonism and cognitive dysfunction
  • Estimation of the 2020 Global Population of Parkinson’s Disease (PD)
  • Patients with Essential Tremor Live Longer than their Relatives
  • Help & Support
  • About Us
  • Cookies & Privacy
  • Wiley Job Network
  • Terms & Conditions
  • Advertisers & Agents
Copyright © 2025 International Parkinson and Movement Disorder Society. All Rights Reserved.
Wiley